PDSB - PDS Biotech

-

$undefined

N/A

(N/A)

PDS Biotech NasdaqCM:PDSB PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies. The company's lead product candidate is Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate, tumor-targeting interleukin 12 immune-cytokine that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment. Further, the company provides PDS0202, a novel investigational influenza vaccine that protects against the strains predicted to be prevalent in an upcoming flu season. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Princeton, New Jersey.

Location: 303A College Road East, Suite 300, Princeton, NJ, 08540, United States | Website: https://www.pdsbiotech.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

43.69M

Cash

41.69M

Avg Qtr Burn

N/A

Short % of Float

7.26%

Insider Ownership

3.09%

Institutional Own.

18.11%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Versamune® HPV (PDS0101) + Keytruda Details
Head and neck squamous cell carcinoma

Phase 3

Data readout

Versamune® HPV + PDS01ADC + pembrolizumab Details
Head and neck squamous cell carcinoma

Phase 2

Data readout

Phase 2

Data readout

PDS01ADC + ICI Details
Human papillomavirus

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Update

PDS01ADC Details
Kaposi Sarcoma

Phase 1/2

Data readout

Phase 1/2

Data readout

PDS0301 + Docetaxel Details
Cancer, Prostate cancer

Phase 1/2

Data readout

Phase 1/2

Data readout

Versamune® HPV + PDS01ADC Details
Metastatic colorectal cancer

Phase 1/2

Update